Bavarian Nordic (DB:BV3) - Cotización, noticias y análisis

Resumen acción BV3

Bavarian Nordic A/S desarrolla, fabrica y comercializa vacunas que salvan vidas.

BV3 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 92.6% por debajo de nuestra estimación de su valor razonable

Ha pasado a ser rentable este año

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Se prevé que los beneficios disminuyan una media de 25.9% al año durante los próximos 3 años.

Grandes partidas extraordinarias que afectan a los resultados financieros

Competidores de Bavarian Nordic A/S

Biotest

XTRA:BIO3

€1.4b

Dermapharm Holding

XTRA:DMP

€1.8b

Gerresheimer

XTRA:GXI

€3.4b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$1.8b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Bavarian Nordic
Historical stock prices
Current Share Price	kr.20.50
52 Week High	kr.29.65
52 Week Low	kr.16.77
Beta	1.33
1 Month Change	-3.71%
3 Month Change	-2.94%
1 Year Change	-17.93%
3 Year Change	-46.10%
5 Year Change	11.63%
Change since IPO	-2.38%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	BV3	DE Biotechs	Mercado DE
7D	2.5%	-1.7%	-1.7%
1Y	-17.9%	-15.7%	1.4%

Rentabilidad vs. Industria: BV3 obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del 25.8%.

Rentabilidad vs. Mercado: BV3 obtuvo unos resultados inferiores a los del mercado German, que fue del -1.4% el año pasado.

Volatilidad de los precios

Is BV3's price volatile compared to industry and market?
BV3 volatility
BV3 Average Weekly Movement	5.6%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	9.8%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: BV3 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BV3 (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1992	1,379	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S desarrolla, fabrica y comercializa vacunas que salvan vidas. La empresa ofrece vacunas no replicantes contra la viruela y la viruela del mono con los nombres IMVAMUNE, IMVANEX y JYNNEOS; vacuna antirrábica para uso humano con el nombre Rabipur/RabAvert; vacuna contra la encefalitis transmitida por garrapatas con el nombre Encepur; y vacuna contra el ébola con el nombre MVABEA. También está desarrollando MVA-BN para el tratamiento de la viruela; MVA-BN RSV, que se encuentra en ensayos clínicos de fase III para el tratamiento del virus respiratorio sincitial; ABNCoV2 que ha completado el ensayo clínico de fase III para el tratamiento del SARS-CoV-2.

Resumen de fundamentos de Bavarian Nordic A/S

¿Cómo se comparan los beneficios e ingresos de Bavarian Nordic con su capitalización de mercado?
Estadísticas fundamentales de BV3
Capitalización bursátil	€1.60b
Beneficios(TTM)	€197.71m
Ingresos (TTM)	€946.53m

8.0x

Ratio precio-beneficio (PE)

1.7x

Ratio precio-ventas (PS)

¿Está BV3 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BV3
Ingresos	kr.7.06b
Coste de los ingresos	kr.1.90b
Beneficio bruto	kr.5.16b
Otros gastos	kr.3.69b
Beneficios	kr.1.48b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 08, 2024

Beneficios por acción (BPA)	18.93
Margen bruto	73.07%
Margen de beneficio neto	20.89%
Ratio deuda/patrimonio	0.2%

¿Cómo se ha desempeñado BV3 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción BV3

Recompensas

Análisis de riesgos

Competidores de Bavarian Nordic A/S

XTRA:BIO3

€1.4b

XTRA:DMP

€1.8b

XTRA:GXI

€3.4b

NasdaqCM:CPRX

US$1.8b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Recent updates

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 17%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 24%

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Now 22% undervalued

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold €68k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings released: kr.3.40 loss per share (vs kr.2.40 loss in 2Q 2021)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

First quarter 2022 earnings released

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Less than half of directors are independent

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Executive Officer Tommi Kainu has left the company

Third quarter 2021 earnings released: kr.1.30 loss per share (vs kr.0.50 profit in 3Q 2020)

Second quarter 2021 earnings released: kr.2.40 loss per share (vs kr.2.20 profit in 2Q 2020)